Share:
“Grand View Research, Inc. – Market Research And Consulting.”
According to report published by Grand View Research, The rising prevalence of castrate-resistant prostate cancer, growing adoption of novel drugs, along with an unhealthy lifestyle are key factors anticipated to accelerate market growth. The need for faster treatment options and investments in R&D by key players is also fueling the growth rate of the market.
Castrate-resistant Prostate Cancer Market Growth & Trends
The global
castrate-resistant prostate cancer market size is expected to reach USD 16.2 billion by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.4% from 2020 to 2027. This growth is driven by the rising global burden of castrate-resistant prostate cancer and unhealthy lifestyle.
IMBRUVICA® (ibrutinib) U S Prescribing Information Updated to Include Long-Term Data for Waldenström s Macroglobulinemia (WM)
hometownregister.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hometownregister.com Daily Mail and Mail on Sunday newspapers.
Pharmacist Contributions to Patient Care in Cervical and Endometrial Cancers: From Prevention to Metastatic Disease
pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.
Growing evidence supports the important role of biosimilars in healthcare
New data released at the ASCO Quality Care Symposium continues to underscore the cost-effectiveness of biosimilar treatment options in cancer care
Access to healthcare, including affordable medicines, remains a top concern across the US.
As we advance solutions, new data released at the American Society of Clinical Oncology (ASCO) Quality Care Symposium supports biosimilars as lower-cost, effective treatment options.
In recent years, complex biologic medicines have changed the way we respond to and treat some of the most challenging diseases, including cancer. However, biologics are often challenging to develop and costly to produce.
ABBVie announced today that the U.S. Food and Drug Administration approved the update of the IMBRUVICA ® Prescribing Information to include efficacy and safety data for the combination of IMBRUVICA with rituximab for the treatment of Waldenström’s macroglobulinemia based on the final analysis of the Phase 3 iNNOVATE study. First approved in 2013, IMBRUVICA is currently available to patients with several types of …
– ABBVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) approved the update of the IMBRUVICA ® (ibrutinib) Prescribing Information to include efficacy and safety data for the combination of IMBRUVICA with rituximab for the treatment of Waldenström’s macroglobulinemia (WM), based on the final analysis of the Phase 3 iNNOVATE study. First approved in 2013, IMBRUVICA is currently available to patients with several types of blood cancer, as well as chronic graft-versus-host disease. It was approved as a monotherapy for WM in 2015 and